MedTrace Logo

Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia

NCT00513175 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2012-11-09

No results posted yet for this study

Summary

The primary objective of this study is to examine transplant related mortality (TRM) at 100 days \<30%. A TRM of \>50% is considered unacceptable. This study also seeks a TRM at 12 months that is \<50%, engraftment \>90% (defined as donor cells \>80% at 6 months), and 1 year overall survival \>50%.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Charles A. Linker, M.D. · University of California, San Francisco

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00513175 on ClinicalTrials.gov